Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.45 -0.3%	$1.39	$1.05 ▼ $5.17	$155.93M	0.38	1.21 million shs	402,410 shs
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	2 shs
LPTX Leap Therapeutics	$0.29	$0.37	$0.22 ▼ $4.79	$12.07M	-0.28	1.09 million shs	292,332 shs
NLNK NewLink Genetics		$9.07	$0.82 ▼ $3.60	$162.00M	1.17	547,540 shs	N/A
SCYX SCYNEXIS	$0.73 +1.5%	$0.85	$0.66 ▼ $2.29	$28.54M	1.57	161,476 shs	70,952 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-0.34%	-7.37%	-1.70%	+3.21%	+25.65%
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
LPTX Leap Therapeutics	0.00%	+2.97%	-22.27%	+8.43%	-84.26%
NLNK NewLink Genetics	0.00%	0.00%	0.00%	0.00%	+97.27%
SCYX SCYNEXIS	+1.51%	-0.75%	-17.29%	-12.98%	-62.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.4314 of 5 stars	3.6	2.0	0.0	0.0	1.9	1.7	0.6
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	1.4469 of 5 stars	3.0	2.0	0.0	0.0	0.6	0.0	1.3
NLNK NewLink Genetics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	0.2779 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	572.27% Upside
ALPN Alpine Immune Sciences	0.00	N/A	N/A	N/A
LPTX Leap Therapeutics	2.00	Hold	$3.38	1,071.88% Upside
NLNK NewLink Genetics	0.00	N/A	N/A	N/A
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALPN, SCYX, ACRS, LPTX, and NLNK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	8.36	N/A	N/A	$1.44 per share	1.00
ALPN Alpine Immune Sciences	$56.52M	78.85	N/A	N/A	$4.85 per share	13.40
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.91 per share	N/A
NLNK NewLink Genetics	$940K	0.00	N/A	N/A	$2.11 per share	0.00
SCYX SCYNEXIS	$2.63M	10.85	N/A	N/A	$1.45 per share	0.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-65.17%	-14.86%	-11.82%	N/A
LPTX Leap Therapeutics	-$67.56M	-$1.70	N/A	N/A	N/A	N/A	-162.15%	-120.05%	8/11/2025 (Estimated)
NLNK NewLink Genetics	-$42.99M	-$1.03	N/A	N/A	N/A	-4,592.84%	-41.50%	-33.95%	N/A
SCYX SCYNEXIS	-$21.29M	-$0.56	N/A	14.62	N/A	-1,030.04%	-53.47%	-32.86%	8/6/2025 (Estimated)

Latest ALPN, SCYX, ACRS, LPTX, and NLNK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SCYX SCYNEXIS	-$0.23	-$0.17	+$0.06	-$0.11	$0.14 million	$0.26 million
5/13/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	N/A	N/A
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
NLNK NewLink Genetics	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
ALPN Alpine Immune Sciences	N/A	9.56	9.56
LPTX Leap Therapeutics	N/A	2.41	2.41
NLNK NewLink Genetics	N/A	7.98	7.98
SCYX SCYNEXIS	N/A	5.83	5.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
ALPN Alpine Immune Sciences	75.17%
LPTX Leap Therapeutics	30.46%
NLNK NewLink Genetics	32.32%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
ALPN Alpine Immune Sciences	42.30%
LPTX Leap Therapeutics	7.50%
NLNK NewLink Genetics	12.70%
SCYX SCYNEXIS	4.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
ALPN Alpine Immune Sciences	142	68.60 million	39.58 million	Optionable
LPTX Leap Therapeutics	40	41.44 million	38.33 million	Optionable
NLNK NewLink Genetics	55	37.33 million	N/A	Not Optionable
SCYX SCYNEXIS	60	39.02 million	37.12 million	Optionable

ALPN, SCYX, ACRS, LPTX, and NLNK Headlines

Recent News About These Companies

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

May 30, 2025 | nasdaq.com

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 28, 2025 | insidermonkey.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025 | globenewswire.com

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finance.yahoo.com

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting

April 9, 2025 | markets.businessinsider.com

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.comQ

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

October 30, 2024 | finance.yahoo.com

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

October 10, 2024 | globenewswire.com

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

October 7, 2024 | finance.yahoo.com

SCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News Summary

October 3, 2024 | benzinga.com

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

October 3, 2024 | globenewswire.com

SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Acquires 20,000 Shares

September 17, 2024 | insidertrades.com

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

August 27, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, SCYX, ACRS, LPTX, and NLNK Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.44 -0.01 (-0.34%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$1.44 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Leap Therapeutics NASDAQ:LPTX

$0.29 0.00 (0.00%)

Closing price 07/3/2025 03:13 PM Eastern

Extended Trading

$0.29 0.00 (0.00%)

As of 07/3/2025 04:49 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

NewLink Genetics NASDAQ:NLNK

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

SCYNEXIS NASDAQ:SCYX

$0.73 +0.01 (+1.51%)

Closing price 07/3/2025 02:22 PM Eastern

Extended Trading

$0.72 -0.02 (-2.19%)

As of 07/3/2025 04:02 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time